Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Cell Therapy HLCM051 Fails to Improve Stroke Outcomes Despite Safe Profile
January 24th 2024Although there were no significant differences in the primary end secondary end points, patients with mRS scores of 0 to 2 at day 90 seemed to show better outcomes in the cell therapy group, particularly for those with ischemic core volumes of 50 mL or greater.
Quality of Life in Parkinson Disease Maintained After 5 Years of Subthalamic DBS
January 20th 2024The study provided the first class IIb evidence of the long-term benefits of deep brain stimulation in patients with Parkinson disease, emphasized by improved quality of life and reduced medication requirements.
Dosing Underway for PIERRE Pivotal Study of ThecaFlex DRx System and Nusinersen
January 11th 2024The study investigates the potential benefits of ThecaFlex DRx System, an implantable intrathecal catheter, for patients with SMA treated with nusinersen, aiming to reduce the need for serial lumbar punctures and enhance the overall administration experience.
Dyne Reports Positive Phase 1/2 Data for Duchenne Agent DYNE-251
January 6th 2024After 6 months of treatment, once every 4-week administration of DYNE-251 reached levels of dystrophin expression, exon skipping, and percent dystrophin positive fibers that exceeded levels reported in a previous trial of eteplirsen, considered the standard of care.